Alpha DNA Investment Management LLC Acquires 163 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Alpha DNA Investment Management LLC grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 7.8% in the fourth quarter, Holdings Channel reports. The firm owned 2,255 shares of the biotechnology company’s stock after acquiring an additional 163 shares during the period. Alpha DNA Investment Management LLC’s holdings in United Therapeutics were worth $796,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in UTHR. Cerity Partners LLC grew its stake in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $4,098,000 after acquiring an additional 2,702 shares in the last quarter. Milestone Asset Management LLC boosted its holdings in shares of United Therapeutics by 56.5% in the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 1,037 shares during the period. Korea Investment CORP grew its stake in United Therapeutics by 6.2% in the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company’s stock worth $13,863,000 after purchasing an additional 2,300 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in United Therapeutics by 9.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after purchasing an additional 789 shares during the period. Finally, JPMorgan Chase & Co. raised its position in United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after purchasing an additional 50,291 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on UTHR. HC Wainwright reissued a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

Insider Activity at United Therapeutics

In related news, Director Raymond Dwek sold 4,000 shares of United Therapeutics stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the completion of the sale, the director now directly owns 1,750 shares in the company, valued at $497,962.50. This trade represents a 69.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $940,373.07. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 80,500 shares of company stock valued at $27,849,960 in the last ninety days. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Stock Down 0.2 %

Shares of United Therapeutics stock opened at $284.73 on Friday. The company has a market cap of $12.79 billion, a P/E ratio of 12.50, a PEG ratio of 0.97 and a beta of 0.63. The firm’s 50 day moving average price is $317.98 and its 200-day moving average price is $349.16. United Therapeutics Co. has a 52-week low of $233.28 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the firm posted $4.36 earnings per share. As a group, equities research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.